Literature DB >> 23988409

Design, synthesis, biological evaluation and docking study of 5-oxo-4,5-dihydropyrano[3,2-c]chromene derivatives as acetylcholinesterase and butyrylcholinesterase inhibitors.

Mehdi Khoobi1, Masoumeh Alipour, Amirhossein Sakhteman, Hamid Nadri, Alireza Moradi, Mehdi Ghandi, Saeed Emami, Alireza Foroumadi, Abbas Shafiee.   

Abstract

A series of fused coumarins namely 5-oxo-4,5-dihydropyrano[3,2-c]chromenes linked to N-benzylpyridinium scaffold were synthesized and evaluated as acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) inhibitors. The 1-(4-fluorobenzyl)pyridinium derivative 6g showed the most potent anti-AChE activity (IC50 value=0.038 μM) and the highest AChE/BuChE selectivity (SI>48). The docking study permitted us to rationalize the observed structure-affinity relationships and to detect possible binding modes.
Copyright © 2013 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Acetylcholinesterase; Alzheimer's disease; Chromenes; Coumarins; Docking study

Mesh:

Substances:

Year:  2013        PMID: 23988409     DOI: 10.1016/j.ejmech.2013.07.038

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  8 in total

1.  Design, synthesis, in vivo and in vitro studies of 1,2,3,4-tetrahydro-9H-carbazole derivatives, highly selective and potent butyrylcholinesterase inhibitors.

Authors:  Roshanak Ghobadian; Roghaieh Esfandyari; Hamid Nadri; Alireza Moradi; Mohammad Mahdavi; Tahmineh Akbarzadeh; Hossein Khaleghzadeh-Ahangar; Najmeh Edraki; Mohammad Sharifzadeh; Mohsen Amini
Journal:  Mol Divers       Date:  2019-03-29       Impact factor: 2.943

2.  Design, synthesis, and evaluation of novel cinnamic acid-tryptamine hybrid for inhibition of acetylcholinesterase and butyrylcholinesterase.

Authors:  Shahrzad Ghafary; Roshanak Ghobadian; Mohammad Mahdavi; Hamid Nadri; Alireza Moradi; Tahmineh Akbarzadeh; Zahra Najafi; Mohammad Sharifzadeh; Najmeh Edraki; Farshad Homayouni Moghadam; Mohsen Amini
Journal:  Daru       Date:  2020-05-05       Impact factor: 3.117

Review 3.  Profiling donepezil template into multipotent hybrids with antioxidant properties.

Authors:  Eva Mezeiova; Katarina Spilovska; Eugenie Nepovimova; Lukas Gorecki; Ondrej Soukup; Rafael Dolezal; David Malinak; Jana Janockova; Daniel Jun; Kamil Kuca; Jan Korabecny
Journal:  J Enzyme Inhib Med Chem       Date:  2018-12       Impact factor: 5.051

Review 4.  Molecular docking studies of coumarin hybrids as potential acetylcholinesterase, butyrylcholinesterase, monoamine oxidase A/B and β-amyloid inhibitors for Alzheimer's disease.

Authors:  Samina Khan Yusufzai; Mohammad Shaheen Khan; Othman Sulaiman; Hasnah Osman; Dalily Nabilah Lamjin
Journal:  Chem Cent J       Date:  2018-12-04       Impact factor: 4.215

5.  Zr@IL-Fe3O4 MNPs as an efficient and green heterogeneous magnetic nanocatalyst for the one-pot three-component synthesis of highly substituted pyran derivatives under solvent-free conditions.

Authors:  Mehraneh Aghaei-Hashjin; Asieh Yahyazadeh; Esmayeel Abbaspour-Gilandeh
Journal:  RSC Adv       Date:  2021-07-05       Impact factor: 4.036

6.  2-Amino-4-aryl-5-oxo-4,5-dihydropyrano[3,2-c]chromene-3-carbonitriles with Microtubule-Disruptive, Centrosome-Declustering, and Antiangiogenic Effects in vitro and in vivo.

Authors:  Leonhard H F Köhler; Sebastian Reich; Gerrit Begemann; Rainer Schobert; Bernhard Biersack
Journal:  ChemMedChem       Date:  2022-03-16       Impact factor: 3.540

Review 7.  Recent developments in the design and synthesis of benzylpyridinium salts: Mimicking donepezil hydrochloride in the treatment of Alzheimer's disease.

Authors:  Saghi Sepehri; Mina Saeedi; Bagher Larijani; Mohammad Mahdavi
Journal:  Front Chem       Date:  2022-09-26       Impact factor: 5.545

8.  Phenoxyethyl Piperidine/Morpholine Derivatives as PAS and CAS Inhibitors of Cholinesterases: Insights for Future Drug Design.

Authors:  Yaghoub Pourshojaei; Ardavan Abiri; Khalil Eskandari; Zahra Haghighijoo; Najmeh Edraki; Ali Asadipour
Journal:  Sci Rep       Date:  2019-12-27       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.